]>
IRCT20180421039369N2 IRCT 2019-05-10 Kermanshah University of Medical Sciences The study of the efficacy of the Transdiagnostic Treatment of the Unified for the Improvement of Comorbid Psychological Disorders in Ms Patients The study of the efficacy of the Transdiagnostic Treatment of the Unified for the Improvement of Comorbid Psychological Disorders (Depression, Anxiety and Health Anxiety), Fatigue and Quality of Life in Patients with Multiple Sclerosis (Ms) 2019-05-19 anticipated 45 Complete https://irct.ir/trial/39402 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: For randomizing assignment, the Simple Random method is used. 45 cards with the same appearance are provided. On 15 of cards the number 1 and on 30 of them the number 2 is written which represent the intervention group and the control group respectively. Then, one card is given to each qualified individual randomly and his assignment to the group is recorded. This process is continues until all individuals are assigned. It should be noted that participants are unaware of the nature of the numbers and type of intervention. N/A comorbidity of Psychological disorders in Patient with MS. Intervention 1: Intervention group:In this study, the Barlow unified protocol for transdiagnostic treatment method will be used.The sample size in this study is 45. They are randomly divided into two experimental and control groups, in which 15 subjects in the experimental group and 30 in the control group are placed and the program The treatment, along with the workbook, will be provided to an individual group for 12 consecutive sessions. The treatment sessions are divided into eight sections: Section 1: Increased motivation for participation in treatment, Section 2: Psychological training and tracking emotional experiences, Section 3: Exercise Excitement Education Section, 4) Assess and modify cognitive assessment, Section 5) Avoid Excitement and Excitement, Section 6) Awareness of physical feelings and tolerance with them, Section 7) Exposure to internal and external triggers of excitement, Section 8) Prevention of recurrence. Intervention 2: Control group: Control group: consists of 30 people who are waiting in the waiting list and do not receive treatment during the time of intervention. but after treatment, they will receive Transdiagnostic Treatment of the Unified Protocol for maintaining the ethics of the control group. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no more information
public sasan amiri
Faculty of Medicine, Imam Reza Hospital, Shahid Shiroudi Blvd, Kermanshah
Kermanshah Iran (Islamic Republic of) 6715847141 +98 84 3442 3968 sasanamiri2910@gmail.com Kermanshah University of Medical Sciences scientific sasan amiri
Faculty of Medicine, Imam Reza Hospital, Shahid Shiroudi Blvd, Kermanshah
Kermanshah Iran (Islamic Republic of) 6715847141 +98 84 3442 3968 sasanamiri2910@gmail.com Kermanshah University of Medical Sciences Iran (Islamic Republic of) Suffering Ms disease with diagnosis of the neurological department Having a score of less than 5 in the (EDSS) Disability Indicator based on a neurologist's assessment to determine the individual's ability to attend a therapeutic session The age range is between 50 to 18 years old Affliction of emotional coexistence disorders including depression, anxiety and health anxiety based on diagnostic interview by psychologist Motivation and satisfaction for participation during treatment and research implementation Failure to receive psychological treatment in the past year Have at least a cycle of educationNot having other chronic diseases such as severe liver disorder The lack of current diagnosis of any mental disorder is consistent in Diagram 1 and 2 based on a psychologist's diagnostic interview, with the exception of emotional disorders including depression, anxiety and health anxiety No obvious risk of suicide now There is no history of drug abuse or dependence at the current time and within one year before the start of treatment 18 years 50 years Both Unwillingness to attend research meetings Not attending at least 50% of the sessions Creating severe physical problems so that it can not be present at meetings F06.8 Other specified mental disorders due to brain damage and dysfunction and to physical disease Behavior N/A Intervention group:In this study, the Barlow unified protocol for transdiagnostic treatment method will be used.The sample size in this study is 45. They are randomly divided into two experimental and control groups, in which 15 subjects in the experimental group and 30 in the control group are placed and the program The treatment, along with the workbook, will be provided to an individual group for 12 consecutive sessions. The treatment sessions are divided into eight sections: Section 1: Increased motivation for participation in treatment, Section 2: Psychological training and tracking emotional experiences, Section 3: Exercise Excitement Education Section, 4) Assess and modify cognitive assessment, Section 5) Avoid Excitement and Excitement, Section 6) Awareness of physical feelings and tolerance with them, Section 7) Exposure to internal and external triggers of excitement, Section 8) Prevention of recurrence Control group: Control group: consists of 30 people who are waiting in the waiting list and do not receive treatment during the time of intervention. but after treatment, they will receive Transdiagnostic Treatment of the Unified Protocol for maintaining the ethics of the control group. Comorbidity of psychological disorders of patients with MS. Timepoint: A week before the intervention, one week after the intervention, Three months after the intervention. Method of measurement: Beck Depression Inventory (BDI-II), Beck Anxiety Inventory, Short form Health Anxiety Scale (SHIA), Fatigue Exercise Scale (FSS), and Quality of Life Scale (MSQOL-54) questionnaire. Depression. Timepoint: A week before the intervention, one week after the intervention, three months after the intervention. Method of measurement: Beck Depression Inventory (BDI-II). Anxiety. Timepoint: A week before the intervention, one week after the intervention, three months after the intervention. Method of measurement: Beck Anxiety Inventory. Health Anxiety. Timepoint: A week before the intervention, one week after the intervention, three months after the intervention. Method of measurement: Short Form Health Anxiety Scale (SHIA). Fatigue Severity. Timepoint: A week before the intervention, one week after the intervention, three months after the intervention. Method of measurement: Fatigue Severity Scale (FSS). Quality of Life. Timepoint: A week before the intervention, one week after the intervention, three months after the intervention. Method of measurement: Multiple Sclerosis Quality of Life-54 (MSQOL-54). Kermanshah University of Medical Sciences Approved 2019-04-24 Ethics Committee of Kermanshah University of Medical Sciences Central Building of Kermanshah University of Medical Sciences, Shahid Beheshti Blvd, Kermanshah Kermanshah Kermanshah Iran (Islamic Republic of)